MedicaidCoverageMedium impact
Maryland Medicaid to cover cell and gene therapy for sickle cell disease
UnitedHealthcare·MD · Hematology, Oncology, Internal Medicine +2 more·State news
Effective date
Jan 1, 2026
We identified it
Jun 13, 2026
Summary
Starting January 1, 2026, Maryland Medicaid now covers FDA-approved cell and gene therapies (Casgevy and Lyfgenia) for sickle cell disease through the Cell and Gene Therapy Access Model. Coverage includes evaluation, apheresis, infusion, recovery and long-term follow-up at authorized treatment centers.
Action Required
Immediately: Providers treating sickle cell disease patients should discuss cell and gene therapy options with eligible Maryland Medicaid members and refer them for evaluation at authorized treatment centers as appropriate. Review Maryland Department of Health guidelines for clinical information and eligibility criteria.